Skip to main content
Fig. 8 | Journal of Nanobiotechnology

Fig. 8

From: A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease

Fig. 8

C44-Fc treatment relieves hepatic steatosis induced by HF/HCCD feeding. Body weight (a), representative liver morphology (b) and liver weight (c) of mice were presented (n = 6). d The TG contents of livers were measured (n = 5) by commercial kits. e Representative H&E staining of liver tissues. f Representative images and quantification (g) of oil red O staining are presented (n = 3). The levels of Serum ALT (h) and AST (i) were measured at the terminus of the research (n = 6). § and * respectively represent the Student’s t-test of 25 mg/kg of C44-Fc and 25 mg/kg of evinacumab treatment compared with control Ab

Back to article page